Skip to main content
. 2020 Nov 7;26(41):6455–6474. doi: 10.3748/wjg.v26.i41.6455

Figure 1.

Figure 1

Structure of the decision analytic model assessing the cost-effectiveness of infliximab maintenance therapy relative to conventional maintenance therapy for moderate to severe Crohn’s disease in China. CMT: Conventional maintenance therapy; IMT: Infliximab maintenance therapy; MS-CD: Moderate to severe Crohn’s disease.